18. Mortality: numbers of deaths in treatment and placebo groups in included studies.
| Study ID | Antibiotic class | Antibiotic | Placebo or control or standard treatment |
| Albert 2011 | Macrolide | AZM: 18/570 (3%) | 20/572 (4%) |
| Banerjee 2005 | Macrolide | CLR: 0/31 | 0/36 |
| Berkhof 2013 | Macrolide | AZM: 0/42 | 0/42 |
| Blasi 2010 | Macrolide | AZM: 1/11 (9%) | 5/11 (45%) |
| Brill 2015 | Quinolone Tetracycline Macrolide |
MOX: 0/25 DOX: 0/25 AZM: 0/25 |
0/24 |
| He 2010 | Macrolide | ERY: 0/18 | 0/18 |
| Mygind 2010 | Macrolide | AZM: 74/287 (25%) | 81/288 (28%) |
| Seemungal 2008 | Macrolide | ERY: 0/53 (0%) | 1/56 (2%) |
| Sethi 2010 | Quinolone | MOX: 13/753 (2%) | 13/584 (2%) |
| Shafuddin 2015 | Macrolide+ tetracycline |
ROX: 3/97 (3%) DOX+ROX: 5/101 (5%) |
5/94 (5%) |
| Simpson 2014 | Macrolide | AZM: 0/15 | 0/15 |
| Singh 2019 | Tetracycline | DOX: 0/30 | 0/30 |
| Suzuki 2001 | Macrolide | ERY: 0/55 | 0/54 |
| Tan 2016 | Macrolide | ERY: 0/18 | 0/18 |
| Uzun 2014 | Macrolide | AZM: 0/47 (0%) | 2/45 (4%) |
| Vermeersch 2019 | Macrolide | AZM: 3/147 (2%) | 6/154 (3%) |
| Wang 2017 | Macrolide | AZM: 0/43 | 0/43 |
Abbreviations
AZM: azithromycin; CLR: clarithromycin; DOX: doxycycline; ERY: erythromycin; MOX: moxifloxacin; ROX: roxithromycin.